Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
BioStreamline project outcomes

BioStreamline project outcomes

BioStreamline: Streamlining the development of next generation biotherapeutics

BioStreamline: Streamlining the development of next generation biotherapeutics

Dupilumab provides clinical benefit to adolescents with moderate-to-severe atopic dermatitis

Dupilumab provides clinical benefit to adolescents with moderate-to-severe atopic dermatitis

Analyses of two clinical trials predict response to asthma drug by COPD patients

Analyses of two clinical trials predict response to asthma drug by COPD patients

Lung cancer may soon be picked up by a blood test

Lung cancer may soon be picked up by a blood test

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Accelerating Nanobody Production using Polyclonal Anti-VHH Antibodies

Accelerating Nanobody Production using Polyclonal Anti-VHH Antibodies

VUMC partners with Batavia to move promising Zika antibody therapy closer to the clinic

VUMC partners with Batavia to move promising Zika antibody therapy closer to the clinic

UC San Diego researchers identify new therapeutic approach to kill cancer cells

UC San Diego researchers identify new therapeutic approach to kill cancer cells

Scientists step closer to an Ebola cure

Scientists step closer to an Ebola cure

Human apolipoprotein E promotes hepatitis B virus infection

Human apolipoprotein E promotes hepatitis B virus infection

New nanovaccine for deadly skin cancer

New nanovaccine for deadly skin cancer

GW Cancer Center selected as first global clinical trial site for high risk cutaneous squamous cell carcinoma

GW Cancer Center selected as first global clinical trial site for high risk cutaneous squamous cell carcinoma

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

IONTAS and Teva Pharmaceuticals announce new antibody optimization agreement

Servier chooses Pall as single-source supplier for new biomanufacturing facility

Servier chooses Pall as single-source supplier for new biomanufacturing facility

New study uncovers 3D structure of toxin responsible for C. diff infection

New study uncovers 3D structure of toxin responsible for C. diff infection

Veravas launches advanced solutions to address biotin interference in diagnostic tests

Veravas launches advanced solutions to address biotin interference in diagnostic tests

FDA grants accelerated approval to new treatment for refractory multiple myeloma

FDA grants accelerated approval to new treatment for refractory multiple myeloma

Global study reveals viruses as important cause of childhood pneumonia

Global study reveals viruses as important cause of childhood pneumonia

Stability Testing of Therapeutic Proteins using DLS and Machine Learning

Stability Testing of Therapeutic Proteins using DLS and Machine Learning